Welcome to our dedicated page for BRAINSTORM CELL THERAPEUTICS SEC filings (Ticker: BCLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BRAINSTORM CELL THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BRAINSTORM CELL THERAPEUTICS's regulatory disclosures and financial reporting.
HARTOUNIAN HARTOUN reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Hartoun Hartoun received a grant of stock options to buy 225,000 shares of common stock at $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan and expire on February 26, 2036.
The award vests over a short period: 50% of the options vest on the grant date and the remaining 50% vest on the six‑month anniversary, as long as Hartoun remains employed through each vesting date. After this grant, he holds 225,000 stock options directly.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Stacy Lindborg received a grant of stock options to buy 150,000 shares of common stock at $0.70 per share. All 150,000 options were outstanding after the grant.
The options were granted under the company’s 2014 Stock Incentive Plan. According to the terms, 50% of the award vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant date, provided she remains employed through each vesting date. The options expire on February 26, 2036, giving a long-dated incentive tied to the company’s future share performance.
BrainStorm Cell Therapeutics director Naor Nir received a new stock option grant. He was awarded options to buy 180,000 shares of common stock at an exercise price of $0.70 per share under the company’s 2014 Stock Incentive Plan.
According to the vesting terms, 50% of the options vest on the grant date, and the remaining 50% vest on the six‑month anniversary of the grant date, provided he remains employed by the company through each vesting date. Following this award, he holds options covering 180,000 shares from this grant, which expire on February 26, 2036.
BRAINSTORM CELL THERAPEUTICS INC. director Ibrahim B. Dagher received a grant of stock options to acquire 225,000 shares of common stock at an exercise price of $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan as equity-based compensation.
According to the vesting terms, 50% of the award vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant date, as long as Dagher remains employed by the company through each vesting date. Following this grant, his reported holdings in this option series total 225,000 options, which are scheduled to expire on February 26, 2036.
Brainstorm Cell Therapeutics Inc. is registering up to 7,796,496 shares of common stock for resale by existing investors. This includes 1,310,528 outstanding shares, up to 2,233,334 shares issuable on exercise of pre-funded warrants, and up to 4,252,634 shares issuable on exercise of common stock purchase warrants.
The company will not receive proceeds from investor resales, but would receive cash if warrants are exercised, at prices of $0.0005, $1.00, or $1.45 per share. Brainstorm trades on the OTCQB under “BCLI,” last quoted at $0.716 per share, and remains a smaller reporting, pre-revenue biotech focused on its NurOwn cell therapy for ALS and other neurodegenerative diseases, with a history of losses and going-concern risk highlighted among extensive risk factors.
BrainStorm Cell Therapeutics reported first quarter 2026 results and updated progress on its NurOwn ALS program. For the three months ended March 31, 2026, the company recorded a net loss of $2,127 thousand, narrower than the $2,864 thousand loss a year earlier, with a basic and diluted net loss per share of $0.19.
Research and development expenses were $762 thousand and general and administrative expenses were $1,284 thousand. The balance sheet shows cash and cash equivalents of $15 thousand and total assets of $755 thousand versus total liabilities of $11,764 thousand, resulting in stockholders’ deficit of $11,009 thousand as of March 31, 2026.
Management highlighted preparations for the planned Phase 3 ENDURANCE study of NurOwn in ALS, noting that site activation, manufacturing readiness, and regulatory engagement are progressing and that moving into enrollment remains subject to securing the necessary financing.
Brainstorm Cell Therapeutics Inc. reported another quarterly loss and remains under significant financial strain. For the three months ended March 31, 2026, the company recorded a net loss of $2,127 thousand, down from $2,864 thousand a year earlier, driven by lower research and development and general and administrative spending.
Total assets were only $755 thousand against $11,764 thousand of liabilities, resulting in a stockholders’ deficit of $11,009 thousand. Cash and cash equivalents were just $15 thousand at quarter-end, with additional restricted cash of $191 thousand, underscoring severe liquidity pressure.
Operating activities used $1,320 thousand of cash, partially offset by $1,250 thousand from financing, including a $970 thousand private placement and new short-term loans. Management explicitly states that recurring losses, minimal cash, reliance on equity and debt financing, and outstanding convertible and other short-term notes raise substantial doubt about the company’s ability to continue as a going concern.
BrainStorm Cell Therapeutics Inc. describes a challenging year centered on its NurOwn® cell therapy for ALS and related neurodegenerative diseases. A Phase 3 ALS trial did not achieve statistically significant results overall, and an FDA advisory committee later voted 17-1 that NurOwn did not demonstrate substantial evidence of effectiveness for mild to moderate ALS, leading to withdrawal of the Biologics License Application on November 3, 2023.
Subsequently, BrainStorm held a December 2023 FDA meeting and obtained an FDA Special Protocol Assessment on April 9, 2024 and later Chemistry, Manufacturing, and Controls alignment for a planned Phase 3b registrational ALS trial. The company also highlights non-dilutive funding, including a completed $15.9 million CIRM grant, and its expanding exosome platform. It reports an aggregate market value of non-affiliate equity of $10,496,980 as of June 30, 2025 and 11,034,775 common shares outstanding as of March 27, 2026, and notes that its stock was delisted from Nasdaq in July 2025 and now trades on the OTCQB.
BrainStorm Cell Therapeutics Inc. reported full-year 2025 results and a corporate update, highlighting a strategic $2.0 million post–year-end financing to support its NurOwn ALS program and planned Phase 3b confirmatory study under a Special Protocol Assessment with the FDA.
For 2025, the company recorded a net loss of $10.3 million, or $1.11 per share, with operating expenses of $4.2 million for research and development and $5.8 million for general and administrative activities. At December 31, 2025, cash and cash equivalents were $29,000, total assets were $1.0 million, and total liabilities were $11.0 million, resulting in a stockholders’ deficit of $10.0 million.
Brainstorm Cell Therapeutics Inc. entered a Securities Purchase Agreement with an accredited investor for up to $1,000,000 in a private placement of common stock and pre-funded warrants, to be completed in up to eight closings. The first closing on February 24, 2026 delivered $125,000, with up to $875,000 remaining at investor-determined timings.
Securities are priced at $0.60 per share, with pre-funded warrants priced at $0.60 less $0.0005 and exercisable at $0.00005 per share. The company will also issue common warrants exercisable at $1.00 for 120% of the shares and pre-funded warrants purchased. Proceeds are earmarked for working capital, and the company committed to register the resale of these securities and to maintain its stock market listing.
The board also approved amendments to its 2014 stock and global option plans, increasing the shared equity pool by 5,500,000 shares to a total of 8,406,666 shares of common stock available for equity awards to employees, officers and directors.